CoChat

Resveratrol prevents p53 aggregation in vitro and in breast cancer cells

Open access
Ferraz da Costa, Danielly C., Campos, Nathali P.C., Santos, Ronimara A., Guedes-da-Silva, Francisca Hildemagna, Martins-Dinis, Mafalda Maria D.C., Zanphorlin, Letícia, Ramos, Carlos, Rangel, Luciana P., Silva, Jerson L. · 2018 · Oncotarget
Cited by 87

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

// Danielly C. Ferraz da Costa 1, 2 , Nathali P.C. Campos 2, 3 , Ronimara A. Santos 1 , Francisca Hildemagna Guedes-da-Silva 2, 3 , Mafalda Maria D.C. Martins-Dinis 2, 3 , Letícia Zanphorlin 4 , Carlos Ramos 4 , Luciana P. Rangel 2, 5 and Jerson L. Silva 2, 3 1 Departamento de Nutrição Básica e Experimental, Instituto de Nutrição, Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, RJ, Brazil 2 Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil 3 Programa de Biologia Estrutural, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil 4 Instituto de Química, Universidade de Campinas, Campinas 13083-970, SP, Brazil 5 Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil Correspondence to: Jerson L. Silva, email: jerson@bioqmed.ufrj.br Keywords: amyloid aggregation; p53; cancer; aggregation; resveratrol Received: June 22, 2017 Accepted: June 04, 2018 Published: June 26, 2018 ABSTRACT One potential target for cancer therapeutics is the tumor suppressor p53, which is mutated in more than 50% of malignant tumors. Loss of function (LoF), dominant negative (DN) and gain of function (GoF) mutations in p53 are associated with amyloid aggregation. We tested the potential of resveratrol, a naturally occurring polyphenol, to interact and prevent the aggregation of wild-type and mutant p53 in vitro using fluorescence spectroscopy techniques and in human breast cancer cells (MDA-MB-231, HCC-70 and MCF-7) using immunofluorescence co-localization assays. Based on our data, an interaction occurs between resveratrol and the wild-type p53 core domain (p53C). In addition, resveratrol and its derivatives pterostilbene and piceatannol inhibit mutant p53C aggregation in vitro . Additionally, resveratrol reduces mutant p53 protein aggregation in MDA-MB-231 and HCC-70 cells but not in the wild-type p53 cell line MCF-7. To verify the effects of resveratrol on tumorigenicity, cell proliferation and cell migration assays were performed using MDA-MB-231 cells. Resveratrol significantly reduced the proliferative and migratory capabilities of these cells. Our study provides evidence that resveratrol directly modulates p53, enhancing our understanding of the mechanisms involved in p53 aggregation and its potential as a therapeutic strategy for cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.25631

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 87

Metadata

Authors
Ferraz da Costa, D. C., Campos, N. P. C., Santos, R. A., Guedes-da-Silva, F. H., Martins-Dinis, M. M. D. C., Zanphorlin, L., Ramos, C., Rangel, L. P., & Silva, J. L.
Venue
Oncotarget
Published
2018-06-26
Volume
9
Issue
49
Pages
29112-29122
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2810340031
Cited by
87
References
4
FWCI
4.43
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resveratrol prevents p53 aggregation in vitro and in breast cancer cells. https://app.cochat.ai/papers/10.18632/oncotarget.25631
The paper
Ferraz da Costa, D. C., Campos, N. P. C., Santos, R. A., Guedes-da-Silva, F. H., Martins-Dinis, M. M. D. C., Zanphorlin, L., Ramos, C., Rangel, L. P., & Silva, J. L. (2018). Resveratrol prevents p53 aggregation in vitro and in breast cancer cells. Oncotarget. https://doi.org/10.18632/oncotarget.25631

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.